Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Functional and genomic characterization of patient-derived xenograft model to study the adaptation to mTORC1 inhibitor in clear cell renal cell carcinoma.

Cancer medicine - 1 Jan 2021

Sakamoto Hiromasa, Yamasaki Toshinari, Sumiyoshi Takayuki, Takeda Masashi, Shibasaki Noboru, Utsunomiya Noriaki, Arakaki Ryuichiro, Akamatsu Shusuke, Kobayashi Takashi, Inoue Takahiro, Kamba Tomomi, Nakamura Eijiro, Ogawa Osamu

Abstract excerpt

Resistance to the mechanistic target of rapamycin (mTOR) inhibitors, which are a standard treatment for advanced clear cell renal cell carcinoma (ccRCC), eventually develops in most cases. In this study, we established a patient-derived xenograft (PDX) model which acquired resistance to the mTOR inhibitor temsirolimus, and explored the underlying mechanisms of resistance acquisition. Temsirolimus was administered...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Renal Cell
Share to DNA (Cytosine-5-)-Methyltransferase 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mechanistic Target of Rapamycin Complex 1

Share to Mice, SCID

Share to Neoplasm Transplantation

Share to Sirolimus

Share to Tumor Burden

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 33107222
DOI: 10.1002/cam4.3578
PMCID: PMC7826464

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Functional and genomic characterization of patient-derived xenograft model to study the adaptation to mTORC1 inhibitor in clear cell renal cell carcinoma.PMID 33107222Read ↗

Mammalian Target of Rapamycin Inhibitors Resistance Mechanisms in Clear Cell Renal Cell CarcinomaSemantic proximity Read ↗

Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma.Semantic proximity Read ↗

PTEN loss confers sensitivity to rapalogs in clear cell renal cell carcinoma.Semantic proximity Read ↗

Molecular Mechanisms of Drug Resistance in Clear Cell Renal Cell CarcinomaSemantic proximity Read ↗

Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies.Semantic proximity Read ↗

Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.Semantic proximity Read ↗

The implementation of lenvatinib/everolimus or lenvatinib/pembrolizumab combinations in the treatment of metastatic renal cell carcinoma.Semantic proximity Read ↗

Cabozantinib inhibits tumor growth and metastasis of a patient-derived xenograft model of papillary renal cell carcinoma with MET mutation.Semantic proximity Read ↗

Unconventional mechanism of action and resistance to rapalogs in renal cancer.Semantic proximity Read ↗

Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell CarcinomaSemantic proximity Read ↗

Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.Semantic proximity Read ↗

EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome ReprogrammingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.